Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaThree decades of beta-lactamase inhibitorsIdentification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases.Comparison of -lactamases of classes A and D: 1.5-A crystallographic structure of the class D OXA-1 oxacillinaseChemistry and biosynthesis of clavulanic acid and other clavamsClass D β-lactamases: a reappraisal after five decadesUnderexplored niches in research on plant pathogenic bacteriaAmpicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypesInhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.Integron- and carbenicillinase-mediated reduced susceptibility to amoxicillin-clavulanic acid in isolates of multidrug-resistant Salmonella enterica serotype typhimurium DT104 from French patients.New developments and concepts in antimicrobial therapy for intra-abdominal infections.beta-Lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors.In vitro and in vivo activities of AM-112, a novel oxapenem.ESBLs: A Clear and Present Danger?Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates.Assessment of biliary excretion of piperacillin-tazobactam in humansExtended spectrum beta lactamase-producing Klebsiella pneumoniae infections: a review of the literature.Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking.Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Clavulanic acid inhibits MPP⁺-induced ROS generation and subsequent loss of dopaminergic cells.Quantification of Growth of Campylobacter and Extended Spectrum β-Lactamase Producing Bacteria Sheds Light on Black Box of Enrichment Procedures.Multivariate analysis of prognostic factors in patients with pulmonary actinomycosis.In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.Determination of Extended-Spectrum β-Lactamases and AmpC Production in Uropathogenic Isolates of Escherichia coli and Susceptibility to Fosfomycin.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).β-lactam/β-lactamase inhibitor combinations: from then to now.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal DiseaseInhibition of metallo-beta-lactamases by a series of mercaptoacetic acid thiol ester derivatives.In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms.Clavulanic acid does not affect convulsions in acute seizure tests in mice.Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.Homology modeling and virtual screening of inhibitors against TEM- and SHV-type-resistant mutants: A multilayer filtering approach.Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid.Miniaturized fluid array for high-throughput protein expression.Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods.A printable hydrogel microarray for drug screening avoids false positives associated with promiscuous aggregating inhibitors.Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media.Tackling the Antibiotic Resistance Caused by Class A -Lactamases through the Use of -Lactamase Inhibitory Protein
P2860
Q24612271-BCD1FFE0-90C3-43FA-B2E9-C14F0DEEC779Q24646623-3D029D7A-A4DE-44F1-8EE9-204092D70BC1Q27639017-7C9404E0-EDA6-46E8-BE50-C41C1940981BQ27640203-2744537F-543A-45F8-8B41-59F9CA8E030DQ28247865-C36223AB-CAAD-44A4-B9D4-3609E5DC833CQ28295700-8B506E2A-F938-4175-8BA2-D40569CA7CF9Q28752081-F6594528-0A26-44E6-8022-FBF86E63C0EBQ33548223-8EE432BD-00D1-4A09-B82B-136A628E6386Q33647947-F3209882-BAD0-4D36-B1A8-A4C5B775E6B7Q33976221-ECF171B6-7EF3-4F9D-9D01-24AD2BEFD912Q34028070-D547DE28-0769-4B04-A9CC-51E88AE20E1FQ34074695-06839DAB-2218-454C-A967-427E3B508229Q34938276-4D702895-2F0F-4C66-AB2B-4A34CE96C5B2Q35101453-5F97BD78-34D8-413B-9476-65C242AA2266Q35126478-9640DB9D-3A59-4718-B3BA-5F933743C352Q35137461-BDBC69E3-727F-47DB-A636-070C3A8CD10FQ35298431-86B90F9A-58EB-4924-8055-D94781E3565FQ35374914-F44B42C3-23D4-4247-B6E7-A33746829A51Q36571851-BD6ED594-F4B6-4BAD-B54F-135A11ECE65AQ36773385-DC0F6489-3BC6-4F98-9309-C12EC4996D08Q37246787-0A7033E9-54DF-4977-B9D6-D795A5158F9DQ37502815-E14D3D4A-86A7-4789-98EE-D3C2BEFC3645Q37624562-1F4FAA53-F9EC-4968-9EE1-ED7530C1154CQ37670556-39C167BA-E699-4841-8EE2-A333763B8624Q38130715-830E1E6C-1B5B-44F5-BFF6-469464BBB0F5Q38264182-33873E45-D987-4F70-80E9-C4F640568B82Q39066154-5402BE47-C0C3-4BEB-93E3-674E1B7267CCQ39783479-C75E7F89-FC3D-4DA8-96F1-807048F2537BQ39792561-AA4602B2-88FB-4970-B081-9E5EAE8F32BAQ40135754-3917DC61-2D69-46D8-8D55-38F65286F465Q40321694-31576629-C92E-4EA9-9846-55430CC574D2Q40326885-23DA0A0D-8F22-4142-84F1-0CC9474681D6Q41206521-82B843FA-FC14-4F08-AA8C-FC8BB3A0D2BFQ41707283-858C1079-9393-4F97-B5EF-C3F82D3B472AQ42956823-E82A38E8-1ACC-4843-958B-1403502D9E00Q44542004-07099D24-D2B4-4E64-918F-79245FC84B73Q49363191-737C2082-0910-44D1-BD38-F4E53967ECA1Q50284491-0BBB5A2C-7A58-4C32-B8BD-E87C19B74E14Q57174160-CBFA0AF4-0370-4A5A-BBB0-D2AF15277CA3
P2860
Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Comparative activities of clav ...... lly important beta-lactamases.
@en
type
label
Comparative activities of clav ...... lly important beta-lactamases.
@en
prefLabel
Comparative activities of clav ...... lly important beta-lactamases.
@en
P2093
P2860
P356
P1476
Comparative activities of clav ...... lly important beta-lactamases.
@en
P2093
P2860
P304
P356
10.1128/AAC.38.4.767
P407
P577
1994-04-01T00:00:00Z